1. Home
  2. CUE vs PAVS Comparison

CUE vs PAVS Comparison

Compare CUE & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • PAVS
  • Stock Information
  • Founded
  • CUE 2014
  • PAVS 2004
  • Country
  • CUE United States
  • PAVS United States
  • Employees
  • CUE N/A
  • PAVS N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • PAVS Medicinal Chemicals and Botanical Products
  • Sector
  • CUE Health Care
  • PAVS Health Care
  • Exchange
  • CUE Nasdaq
  • PAVS Nasdaq
  • Market Cap
  • CUE 91.9M
  • PAVS 90.2M
  • IPO Year
  • CUE 2018
  • PAVS 2019
  • Fundamental
  • Price
  • CUE $1.26
  • PAVS $1.37
  • Analyst Decision
  • CUE Strong Buy
  • PAVS
  • Analyst Count
  • CUE 5
  • PAVS 0
  • Target Price
  • CUE $5.00
  • PAVS N/A
  • AVG Volume (30 Days)
  • CUE 285.6K
  • PAVS 12.1K
  • Earning Date
  • CUE 03-10-2025
  • PAVS 01-01-0001
  • Dividend Yield
  • CUE N/A
  • PAVS N/A
  • EPS Growth
  • CUE N/A
  • PAVS N/A
  • EPS
  • CUE N/A
  • PAVS N/A
  • Revenue
  • CUE $9,532,000.00
  • PAVS $6,544,819.00
  • Revenue This Year
  • CUE $73.11
  • PAVS N/A
  • Revenue Next Year
  • CUE $11.02
  • PAVS N/A
  • P/E Ratio
  • CUE N/A
  • PAVS N/A
  • Revenue Growth
  • CUE 149.53
  • PAVS N/A
  • 52 Week Low
  • CUE $0.45
  • PAVS $0.32
  • 52 Week High
  • CUE $2.45
  • PAVS $2.50
  • Technical
  • Relative Strength Index (RSI)
  • CUE 45.93
  • PAVS 54.66
  • Support Level
  • CUE $1.20
  • PAVS $1.32
  • Resistance Level
  • CUE $1.50
  • PAVS $1.40
  • Average True Range (ATR)
  • CUE 0.12
  • PAVS 0.04
  • MACD
  • CUE -0.02
  • PAVS -0.01
  • Stochastic Oscillator
  • CUE 16.67
  • PAVS 41.67

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About PAVS Paranovus Entertainment Technology Ltd.

Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.

Share on Social Networks: